Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.95 |
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 0.95 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.61 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.59 |
| ▸ | KCNH2 known ✓ | Q12809 | 4/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.59 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.59 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.59 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.59 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.59 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.59 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.59 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.59 |
| ▸ | CASR known ✓ | P41180 | 1/20 | 0.59 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.59 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.52 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3638413 | 0.98 | HTR2A (1.00) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL11389802 | 0.87 | HTR2A (0.96) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| SCHEMBL28113806 | 0.84 | HTR2A (1.00) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL29009216 | 0.84 | HTR2A (0.68) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| SCHEMBL11381572 | 0.83 | HTR2A (0.72) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| SCHEMBL4811791 | 0.82 | HTR2A (0.70) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| SCHEMBL6900402 | 0.82 | HTR2A (0.70) | HTR2AHRH1CYP3A4SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL11794831 | 0.81 | KCNH2 (0.73) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL2074868 | 0.81 | HTR2A (0.64) | HTR2AHRH1CYP3A4MEN1ALOX15 | |
| Hydrochloric Acid SCHEMBL3830551 | 0.81 | HTR2A (0.64) | HTR2AHRH1CYP3A4MEN1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677512-A | Method for synthesizing lercanidipine intermediate N-methyl-3,3-diphenylpropylamine hydrochloride | 大连万福制药有限公司 | 2023-02-03 | — | — | CN | claimed |
| CN-115677512-A | Method for synthesizing lercanidipine intermediate N-methyl-3,3-diphenylpropylamine hydrochloride | 大连万福制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115677512-A | Method for synthesizing lercanidipine intermediate N-methyl-3,3-diphenylpropylamine hydrochloride | 大连万福制药有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-1824824-A1 | INTERMEDIATES FOR THE PREPARATION OF LERCANIDIPINE | Motivan Ltd. (IL) | 2007-08-29 | — | — | EP | disclosed |
| WO-2006059332-A1 | INTERMEDIATES FOR THE PREPARATION OF LERCANIDIPINE | MOTIVAN LTD. (IL) | 2006-06-08 | — | — | WO | disclosed |
| EP-0825862-A1 | USE OF(S)-ENANTIOMERS OF 1,4-DIHYDROPYRIDINE DERIVATIVES FOR TREATING HEART FAILURE | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 1998-03-04 | — | — | EP | disclosed |
| US-5696139-A | Use of S-enantiomers of 1,4-dihydropyridine derivatives for treating heart failure | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1997-12-09 | — | — | US | disclosed |
| WO-1996035420-A1 | USE OF(S)-ENANTIOMERS OF 1,4-DIHYDROPYRIDINE DERIVATIVES FOR TREATING HEART FAILURE | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1996-11-14 | — | — | WO | disclosed |
| US-4249003-A | Process for polycyclic amines | AKTIEBOLAGET LEO (SE) | 1981-02-03 | — | — | US | disclosed |
| US-4249002-A | Polycyclic amines and intermediates therefor | AKTIEBOLAGET LEO (SE) | 1981-02-03 | — | — | US | disclosed |
| US-4246201-A | Substituted N-(3-phenylthiopropyl)-3,3-diphenyl-propylamines possessing pharmacological activity | ALFA FARMACEUTICI, S.P.A. (IT) | 1981-01-20 | — | — | US | disclosed |